VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway

VERTANICAL Receives First European Marketing Authorization for Exilby® as a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain - Pivotal U.S. Phase 3 trial underway

Raccontata damorningstar.com